 Enlivex Therapeutics Ltd NASDAQ: ENLV and Yale Cancer Center announced a research collaboration to assess the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Allocetra is a macrophage-reprogramming immunotherapy product, a potential therapy combined with approved immune checkpoint inhibitors for hard-to-treat solid tumors. 